Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI dye may shield cancer patients from nerve pain

NCT ID NCT00727922

Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether mangafodipir, an MRI contrast agent with antioxidant properties, could reduce nerve damage caused by oxaliplatin chemotherapy. Researchers enrolled 23 cancer patients who already had moderate nerve problems from oxaliplatin but needed to continue treatment. The goal was to see if mangafodipir could ease neuropathy and allow more chemotherapy cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

23 people

The number who actually took part.

Start date

Jun 2008

Finished

Apr 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * NCI CTC grade 2 or more neuropathy induced by oxaliplatine * At least 18 years old * ECOG PS: 2 or less * Life expectancy longer than 3 months * Written informed consent * Adequate hematologic, liver and renal functions Exclusion Criteria: * Known hypersensibility to oxaliplatine * Cancer resistant to oxaliplatine * Fertile woman or man not willing to use adequate contraception * Pregnant or lactating women * Vitamin B6 administration within 48h prior to mangafodipir administration * Uncontrolled infection * Treatment with any other investigational agent, or participation in another clinical trial within 3 weeks prior to first administration of mangafodipir * Evidence of any other disease or condition that contra-indicates the use of an investigational drug * No Social Security insurance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm toxic encephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Neurotoxic disorders

Contacts and locations

Locations

  • Cochin

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.